Chemodex

Honokiol

CHF 81.00
In stock
CDX-H0139-M01010 mgCHF 81.00
CDX-H0139-M02525 mgCHF 162.00
More Information
Product Details
Synonyms 5,3'-Diallyl-2,4'-dihydroxybiphenyl; NSC 293100
Product Type Chemical
Properties
Formula

C18H18O2

MW 266.33
CAS 35354-74-6
Source/Host Chemicals Plant
Purity Chemicals ≥98% (HPLC)
Appearance Light brown powder.
Solubility Soluble in DMSO (30mg/ml), DMF (30mg/ml) or ethanol (30mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key FVYXIJYOAGAUQK-UHFFFAOYSA-N
Smiles OC1=C(C2=CC(CC=C)=C(O)C=C2)C=C(CC=C)C=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Honokiol is a natural product derived from parts of the plant M. grandiflora used in Oriental herbal medicine. It is a lignan with diverse biological activities, including anticancer, neuroprotective, antithrombotic, anti-inflammatroy, antioxidant, antiviral, analgesic, antimicrobial, metabolic and GABA-modulating properties. Honokiol exerts broad-range anticancer activity in vitro and in vivo such as induction of cell cycle arrest and apoptosis, inhibition of epithelial-mesenchymal transition, inhibiting cell migration, invasion, and metastasis, as well as inducing anti-angiogenesis activity. Honokiol has neuroprotective effects based on its potent antioxidant activity, blockade of glutamate receptors and reduction in neuroinflammation. Honokiol also blocks inflammatory factor production in glial cells through the inhibition on NF-κ activation. It protects against lipid peroxidation by interfering with ROS production and migration. It regulates gamma-aminobutyric acid (GABA) A receptors and it also prevents platelet aggregation. Honokiol has been shown to inhibit hepatitis C virus (HCV) infection in vitro and described as a non-adipogenic PPARγ agonist.

Product References

(1) Y. Fukuyama, et al.; Bioorg. Med. Chem. Lett. 12, 1163 (2002) | (2) K.-T. Liou, et al.; Brain Res 992, 159 (2003) | (3) X. Bai, et al.; J. Biol. Chem. 278, 35501 (2003) | (4) H. Hu, et al.; Acta Pharmacol. Sin. 26, 1063 (2005) | (5) K.S. Ahn, et al.; Mol. Cancer Res. 4, 621 (2006) | (6) S. Dikalov, et al.; Biochem. Pharmacol. 76, 589 (2008) | (7) B.H. Kim J.Y. Cho; Acta. Pharmacol. Sin. 29, 113 (2008) | (8) L.E. Fried & J.L. Arbiser; Antioxid. Redox Signal. 11, 1139 (2009) (Review) | (9) L.K. Chao, et al.; J. Agric. Food Chem. 58, 3472 (2010) | (10) J.L. Shen, et al.; Molecules 15, 6452 (2010) (Review) | (11) K.H. Lan, et al.; Liver Internat. 32, 989 (2012) | (12) A.G. Atanasov, et al.; Biochim. Biophys. Acta 1830, 4813 (2013) | (13) A. Kumar, et al.; Future Med. Chem. 5, 809 (2013) (Review) | (14) A. Woodbury, et al.; Front. Neurol. 4, 130 (2013) (Review) | (15) S. Talarek, et al.; Biofactors 43, 760 (2017) (Review) | (16) C.P. Ong, et al.; Cancers 12, E48 (2019) (Review

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.